Enesi Pharma adds new Scientific Advisory Board member.
M2 EQUITYBITES-July 2, 2019-Enesi Pharma adds new Scientific Advisory Board member
(C)2019 M2 COMMUNICATIONS http://www.m2.com
Enesi Pharma, a pharmaceutical company developing injectable solid dose vaccine products, has added Dr Steven Chatfield to its new Scientific Advisory Board, it was reported yesterday.
Dr Chatfield is an internationally recognised vaccine and infectious disease expert who brings around 40 years' experience in R&D, executive, board and advisory roles across various public and private healthcare organisations focused on this area. He has a track record of success through all stages of product discovery and development leading to registration, and has provided expert advice to industry, government and non-governmental organisations on vaccines, vaccination and public health issues, including biodefence. Presently, he is a non-executive director of the Vaccines Manufacturing & Innovation Centre. He is also a director of the UK Cell and Gene Therapy Catapult and a member of the Scientific Advisory Board of the Jenner Institute at the University of Oxford. He is chairman of Prokarium Ltd. Earlier, Dr Chatfield served as chief scientific officer and executive vice president of Strategic Investments for Emergent BioSolutions, a global vaccine business, and was president and CEO of its UK operation. He was also a director of Vaccitech and a director of the Centre for Emergency Preparedness and Response at the UK Health Protection Agency (now Public Health England).
((Comments on this story may be sent to firstname.lastname@example.org))